7MM Digital Therapeutics for Diabetes Market - 2025-2033

The 7MM digital therapeutics for diabetes market size reached US$ 961.09 million in 2024 and is expected to reach US$ 2,578.46 million by 2033, growing at a CAGR of 11.7% during the forecast period 2025-2033.

Digital therapeutics for diabetes refer to evidence-based, software-driven interventions designed to manage and treat diabetes through digital platforms. These therapeutics use advanced technologies like mobile apps, wearable devices, and cloud-based systems to deliver personalized, real-time treatment strategies and behavioral interventions. The goal is to improve diabetes management, enhance patient outcomes, and prevent complications by leveraging data-driven insights.

Digital therapeutics for diabetes use real-time data from wearables (e.g., continuous glucose monitors) and user inputs (e.g., diet and exercise) to provide personalized recommendations. This helps patients make informed decisions about medication, diet, and physical activity, optimizing their blood glucose levels and overall health.

Market Dynamics: Drivers & Restraints

Rising technological advancements are driving the 7MM digital therapeutics for diabetes market growth

Artificial intelligence (AI) capabilities are being integrated into digital therapeutics to analyze vast amounts of patient data (e.g., glucose levels, activity, diet) in real-time for diabetes and associated chronic conditions. This enables the creation of highly personalized treatment plans that adapt to the individual's specific needs, improving glycemic control and long-term health outcomes. Thus, the key market players are focusing on the advanced artificial intelligence capabilities in their diabetes digital therapeutics.

For instance, in February 2025, Byram Healthcare, a leader in home-based care and part of the Owens & Minor family, launched ByramConnect, a personalized digital health program powered by the Welldoc App. Using the Welldoc App's advanced artificial intelligence capabilities, the program analyzes member data across six dimensions of health to help optimize outcomes for people with type 1 or type 2 diabetes and associated chronic conditions such as hypertension, weight management, and cardiovascular risk, providing Byram members with actionable insights and reports that can be shared with their providers and care teams.

Wearable devices, such as Continuous Glucose Monitors (CGMs), provide real-time, continuous tracking of glucose levels. This allows for better decision-making and timely interventions to prevent hypoglycemia or hyperglycemia. CGM systems that integrate with digital therapeutics platforms, provide continuous feedback to both patients and healthcare providers. This integration improves management efficiency, reduces emergency interventions, and enhances patient quality of life. These advanced CGM systems with advancements such as small sensors and smart transmitters becoming a key trend for market growth.

For instance, in October 2024, Ascensia Diabetes Care, launched the Eversense 365 continuous glucose monitoring (CGM) system, the world's only One-year CGM, for people with diabetes in the U.S. Developed by Senseonics Holdings, Inc., Eversense 365 is the only CGM that provides one year of accurate monitoring with minimal disruptions, enabling confident decisions, long-term peace of mind and enhanced quality of life with just one CGM. Senseonics' CGM system Eversense 365 includes a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

Data privacy and security concerns hamper the growth of digital therapeutics for the diabetes market

Digital therapeutics platforms collect vast amounts of sensitive personal health data. Patients are often reluctant to share this data if they are unsure about how securely it is stored or who can access it. This hesitation can delay or limit the adoption of digital health solutions. Digital therapeutics platforms must comply with stringent regulations like the Health Insurance Portability and Accountability Act (HIPAA) in the U.S., the General Data Protection Regulation (GDPR) in the EU, and similar regulations in other regions. The complex compliance requirements for handling patient data can be a significant barrier to market growth, especially for smaller companies or startups.

There is a lack of universal standards for data protection and security in the digital therapeutics sector. Inconsistent practices across different companies, apps, and devices can leave vulnerabilities that may expose patient information. Cybersecurity risks are a major concern, especially as digital health platforms and wearable devices become more interconnected. Hackers targeting health data can compromise patient safety and trust in digital therapeutics.

For instance, according to the HIPAA Journal, in August 2023, 23 million breached healthcare records are reported. Over the past 12 months, an average of 9,989,003 healthcare records were breached each month. In the year to August 31, 2024, there have been 491 data breaches of 500 or more records, and at least 58,668,002 records are known to have been breached. The average breach size in 2024 is currently 119,487 records, and the median breach size is 4,109 records.

Segment Analysis

The 7MM digital therapeutics for diabetes market is segmented based on product type, application, end-user, and country.

Product Type:

The software solutions in the product type segment are expected to dominate the 7MM digital therapeutics for diabetes market with the highest market share

Software solutions are highly scalable and can be accessed by a wide range of patients, regardless of location. They can be used on mobile phones, tablets, and computers, making them accessible to a larger population, including those in remote areas. Software solutions allow for the customization of diabetes care based on real-time data, such as blood glucose levels, exercise routines, and dietary habits.

The major market players are continuously focusing on software solutions, which further accelerates the market growth. For instance, in November 2024, Medtronic received U.S. Food and Drug Administration (FDA) clearance for its new InPen smartphone app and announced the launch of its new Smart MDI system. Smart MDI was designed to provide real-time insights to users on multiple daily injection (MDI) therapy. It includes the InPen smart insulin pen, the InPen app, and Medtronic's disposable, all-in-one Simplera continuous glucose monitor (CGM), which received U.S. Food and Drug Administration approval

Software solutions enable continuous tracking of vital metrics like blood glucose levels, insulin usage and physical activity. This constant monitoring allows for immediate interventions and reduces the need for frequent in-person visits, thus enhancing patient engagement and improving long-term outcomes.

Competitive Landscape

The major players in the 7MM digital therapeutics for diabetes market include Welldoc, Inc., Omada Health Inc., Glooko, Inc., Azumio Inc., Abbott Laboratories, mySugr GmbH, Dexcom, Inc., Health2Sync, iHealth Labs Inc. and Medtronic plc and among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The 7MM digital therapeutics for diabetes market report delivers a detailed analysis with 39 key tables, more than 26 visually impactful figures and 158 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.